Jack Ball is CEO and a board member at Solulink, a San Diego biotech tools company supplying HybriLink™ technology that enables user attachment of fluorophores to antibodies in 30 minutes with no purification. This technology is highly suited to the multicolor flow cytometry market. He is President, Tyball Associates, LLC, a consulting company bringing 21st century sales and marketing strategies that are highly capital efficient, to companies in the biotech tools space. He is an Adjunct Professor at the University of Michigan, Ross Business School in Entrepreneurial Studies. In addition, he serves on the board of directors of the following eight companies: Aquaro Biosystems where he is Executive Chairman, Celsee Diagnostics, DNA Software, ENT Biotech Solutions, NanoCellect, Swift Bioscience and Carterra. He sold ViroCyt and IntelliCyt in mid-2016 for $16M and $90M respectively as a former board member.
Mr. Ball has a long and proven record for bringing life science products to market and capitalizing on existing product potential. Most recently he was Chief Commercial Officer at Accuri Cytometers where he developed a novel commercialization model that was highly capital efficient. He and the management team sold the company to Becton Dickinson for $205M in March 2011. Prior to Accuri Cytometers, he was CEO of Amnis Corporation, a venture backed technology start-up developing and selling high-end imaging flow cytometers. He has also served as Chief Commercial Officer for Molecular Probes, Inc., the world leader in reagents for cell analysis, including flow cytometry consumables. Prior to that he was with Orchid Biosciences as Sr. VP and General Manager and with Amersham Pharmacia Biotech Inc., where he rose to President, Region North America and was responsible for sales, marketing, and customer support for all products sold in North America.
Current role